AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 51 min read$TWST

Twist Bioscience Insiders Sold Shares Worth Over $9.1M

Twist Bioscience insiders sold shares totaling over $9.1M. Dennis Cho, Patrick Finn, Paula Green, and Adam Laponis sold shares at $188.884 each, with remaining holdings of 63,789, 185,088, 106,632, and 100,576 shares respectively.

Original reporting
tradingview.com
Published Oct 5, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Twist Bioscience Insiders Sold Shares Worth Over $9.1M — source image
Source · tradingview.com
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

The disclosed sales may prompt short‑term price weakness, but the long‑term impact depends on upcoming company developments.

02

Market read

Insider sell‑off of over $9M in TWST shares could weigh on the stock in the short term.

03

What to watch

The sale price was near recent highs, possibly locking in gains after a strong run.

Relevance 5/10Novelty 5/10Timing: after‑hours disclosure

Background

Form 4 filing disclosed insider sales by Twist Bioscience's senior legal, operations, HR, and finance officers.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

Multiple C-suite executives sold a total of over $9.1M in TWST shares at $188.884 per share, reducing their holdings.

Expected impact

likely downward pressure as the market prices in the insider sell-off

Evidence & confidence

C‑suite insiders sold large blocks at a high price, which often precedes a short‑term dip.

Market effects

Sector

Minimal; the sale does not affect the broader biotech sector.

Regional

Limited to investors tracking TWST and related biotech funds.

Global

Low; no global macro implications.

Counterpoint

What could challenge this read

Insider sales could be routine portfolio rebalancing rather than a negative signal.

Key entities

  • Officer
    Dennis Cho

    Senior Vice President, Chief Legal Officer & Corporate Secretary

  • Officer
    Patrick John Finn

    President and Chief Operating Officer

  • Officer
    Paula Green

    Senior Vice President of Human Resources

  • Officer
    Adam Laponis

    Chief Financial Officer

Read at source← All news

Related articles

OCT 5
$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min